{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:28:03Z","timestamp":1778758083241,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":145,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"DOI":"10.1186\/s42358-025-00511-1","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T13:25:10Z","timestamp":1766237110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and safety of tocilizumab in juvenile localised scleroderma patients: a retrospective cohort study in Eastern China"],"prefix":"10.1186","volume":"66","author":[{"given":"Yang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-5861","authenticated-orcid":false,"given":"Jing","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denghuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouwei","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"511_CR1","doi-asserted-by":"publisher","first-page":"1108623","DOI":"10.3389\/fmed.2023.1108623","volume":"10","author":"C Papara","year":"2023","unstructured":"Papara C, De Luca DA, Bieber K, Vorobyev A, Ludwig RJ. Morphea: the 2023 update. Front Med (Lausanne). 2023;10:1108623.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"511_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1046\/j.1365-4362.2002.01469.x","volume":"41","author":"VN Sehgal","year":"2002","unstructured":"Sehgal VN, Srivastava G, Aggarwal AK, Behl PN, Choudhary M, Bajaj P. Localized scleroderma\/morphea. Int J Dermatol. 2002;41(8):467\u201375.","journal-title":"Int J Dermatol"},{"key":"511_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm13237134","volume":"13","author":"T Stein","year":"2024","unstructured":"Stein T, Cieplewicz-Gu\u017ala P, I\u017cykowska K, Pieniawska M, \u017baba R, Da\u0144czak-Pazdrowska A, et al. What is new in Morphea-Narrative review on molecular aspects and new targeted therapies. J Clin Med. 2024;13:23.","journal-title":"J Clin Med"},{"issue":"2","key":"511_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pcl.2013.11.006","volume":"61","author":"E Pope","year":"2014","unstructured":"Pope E, Laxer RM. Diagnosis and management of morphea and lichen sclerosus and atrophicus in children. Pediatr Clin North Am. 2014;61(2):309\u201319.","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"511_CR5","first-page":"73","volume":"24","author":"LS Peterson","year":"1997","unstructured":"Peterson LS, Nelson AM, Su WP, Mason T, O\u2019Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in olmsted County 1960\u20131993. J Rheumatol. 1997;24(1):73\u201380.","journal-title":"J Rheumatol"},{"issue":"4","key":"511_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clindermatol.2013.01.010","volume":"31","author":"N Fett","year":"2013","unstructured":"Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432\u20137.","journal-title":"Clin Dermatol"},{"issue":"5","key":"511_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","volume":"45","author":"F Zulian","year":"2006","unstructured":"Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"511_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/idoj.IDOJ_284_19","volume":"11","author":"R George","year":"2020","unstructured":"George R, George A, Kumar TS. Update on management of morphea (Localized Scleroderma) in children. Indian Dermatol Online J. 2020;11(2):135\u201345.","journal-title":"Indian Dermatol Online J"},{"issue":"3","key":"511_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","volume":"59","author":"S Christen-Zaech","year":"2008","unstructured":"Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385\u201396.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"511_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","volume":"145","author":"JJ Leitenberger","year":"2009","unstructured":"Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545\u201350.","journal-title":"Arch Dermatol"},{"issue":"2","key":"511_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/pde.14074","volume":"37","author":"N Do","year":"2020","unstructured":"Do N, Ringold S, Sullivan E, Brandling-Bennett H. A retrospective study: impact of consensus treatment plans on systemic therapy of pediatric morphea. Pediatr Dermatol. 2020;37(2):278\u201383.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"511_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5114\/reum.2017.72628","volume":"55","author":"J Narbutt","year":"2017","unstructured":"Narbutt J, Ho\u0142drowicz A, Lesiak A. Morphea - selected local treatment methods and their effectiveness. Reumatologia. 2017;55(6):305\u201313.","journal-title":"Reumatologia"},{"issue":"10","key":"511_CR13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/jdv.14466","volume":"31","author":"R Knobler","year":"2017","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017;31(10):1581\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"511_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/BOR.0b013e32835896ce","volume":"24","author":"R Vasquez","year":"2012","unstructured":"Vasquez R, Sendejo C, Jacobe H. Morphea and other localized forms of scleroderma. Curr Opin Rheumatol. 2012;24(6):685\u201393.","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"511_CR15","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998\u20132006.","journal-title":"Arthritis Rheum"},{"key":"511_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2022.09.024","volume":"30","author":"S Lonowski","year":"2022","unstructured":"Lonowski S, Goldman N, Kassamali B, Shahriari N, LaChance A, Vleugels RA. Tocilizumab for refractory morphea in adults: A case series. JAAD Case Rep. 2022;30:27\u20139.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"511_CR17","first-page":"605","volume":"22","author":"A Kreuter","year":"2024","unstructured":"Kreuter A, Moinzadeh P, Kinberger M, Horneff G, Worm M, Werner RN, et al. S2k guideline: diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2024;22(4):605\u201320.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"511_CR18","first-page":"605","volume":"22","author":"A Kreuter","year":"2024","unstructured":"Kreuter A, Moinzadeh P, Kinberger M, Horneff G, Worm M, Werner RN, et al. S2k guideline: diagnosis and therapy of localized scleroderma. JDDG: J Der Deutschen Dermatologischen Gesellschaft. 2024;22(4):605\u201320.","journal-title":"JDDG: J Der Deutschen Dermatologischen Gesellschaft"},{"issue":"12","key":"511_CR19","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3899\/jrheum.081284","volume":"36","author":"T Arkachaisri","year":"2009","unstructured":"Arkachaisri T, Vilaiyuk S, Li S, O\u2019Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12):2819\u201329.","journal-title":"J Rheumatol"},{"issue":"2","key":"511_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","volume":"49","author":"T Arkachaisri","year":"2010","unstructured":"Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA. Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2010;49(2):373\u201381.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"511_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamadermatol.2022.5146","volume":"159","author":"M Blaise","year":"2023","unstructured":"Blaise M, Cardot-Leccia N, Seitz-Polski B, Picard-Gauci A, Bertold C, Passeron T, et al. Tocilizumab for Corticosteroid-Refractory immune checkpoint Inhibitor\u2013Induced generalized morphea. JAMA Dermatology. 2023;159(1):112\u20134.","journal-title":"JAMA Dermatology"},{"issue":"1","key":"511_CR22","first-page":"698313","volume":"2014","author":"Y Yoshida","year":"2014","unstructured":"Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014(1):698313.","journal-title":"Biomed Res Int"},{"issue":"5","key":"511_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1517\/14712598.8.5.669","volume":"8","author":"Y Ohsugi","year":"2008","unstructured":"Ohsugi Y, Kishimoto T. The Recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008;8(5):669\u201381.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"511_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2020.0034","volume":"156","author":"JC O\u2019Brien","year":"2020","unstructured":"O\u2019Brien JC, Nymeyer H, Green A, Jacobe HT. Changes in disease activity and damage over time in patients with morphea. JAMA Dermatology. 2020;156(5):513\u201320.","journal-title":"JAMA Dermatology"},{"key":"511_CR25","doi-asserted-by":"crossref","unstructured":"Ko J, Noviani M, Chellamuthu VR, Albani S, Low AHL. The pathogenesis of systemic sclerosis: the origin of fibrosis and interlink with vasculopathy and autoimmunity. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241814287"},{"key":"511_CR26","doi-asserted-by":"publisher","first-page":"2453265","DOI":"10.1155\/2018\/2453265","volume":"2018","author":"F Cacciapaglia","year":"2018","unstructured":"Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, et al. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on Long-Term Tocilizumab treatment. Mediators Inflamm. 2018;2018:2453265.","journal-title":"Mediators Inflamm"},{"key":"511_CR27","doi-asserted-by":"crossref","unstructured":"Berman M, Ben-Ami R, Berliner S, Anouk M, Kaufman I, Broyde A, et al. The effect of tocilizumab on inflammatory markers in patients hospitalized with serious infections. Case Series and review of literature. Life (Basel). 2021;11(3).","DOI":"10.3390\/life11030258"},{"issue":"9","key":"511_CR28","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1093\/rheumatology\/keae196","volume":"63","author":"H Yoshida","year":"2024","unstructured":"Yoshida H, Magi M, Tamai H, Kikuchi J, Yoshimoto K, Otomo K, et al. Effects of interleukin-6 signal Inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2024;63(9):2515\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"511_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","volume":"5","author":"A Rubbert-Roth","year":"2018","unstructured":"Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A review of recent advances using Tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21\u201342.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"511_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/annrheumdis-2021-220875","volume":"81","author":"RA Symons","year":"2022","unstructured":"Symons RA, Colella F, Collins FL, Rafipay AJ, Kania K, McClure JJ, et al. Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. Ann Rheum Dis. 2022;81(2):214\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"511_CR31","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","volume":"60","author":"SC Li","year":"2021","unstructured":"Li SC, Torok KS, Ishaq SS, Buckley M, Edelheit B, Ede KC, et al. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. Rheumatology (Oxford). 2021;60(8):3817\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"511_CR32","first-page":"199","volume":"14","author":"A Kreuter","year":"2016","unstructured":"Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, et al. German guidelines for the diagnosis and therapy of localized scleroderma. JDDG - J German Soc Dermatology. 2016;14(2):199\u2013216.","journal-title":"JDDG - J German Soc Dermatology"},{"issue":"1","key":"511_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3897\/rrpharmacology.5.33831","volume":"55","author":"GA Batishcheva","year":"2019","unstructured":"Batishcheva GA, Zhdanova OA, Nastausheva TL, Chernov YN. Characteristics of adverse side effects of corticosteroid therapy in children with nephrotic syndrome and methods of Pharmacological correction. Res Results Pharmacol (English ed). 2019;55(1):37\u201343.","journal-title":"Res Results Pharmacol (English ed)"},{"key":"511_CR34","doi-asserted-by":"crossref","unstructured":"Batishcheva GA, Zhdanova OA, Nastausheva TL, Goncharova NY, Chernov YN. New methods to detect early manifestations of adverse side effects of glucocorticosteroids in children. Res Results Pharmacol (English ed). 2018;4(1):27\u201332.","DOI":"10.3897\/rrpharmacology.4.25252"},{"issue":"2","key":"511_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.47391\/JPMA.10573","volume":"74","author":"Z Zulfiqar","year":"2024","unstructured":"Zulfiqar Z, Lanewala F, Khatri S, Bajeer I, Aziz M, Hashmi S. Steroid induced ocular complications in idiopathic nephrotic syndrome: a cross sectional single center study. J Pak Med Assoc. 2024;74(2):315\u20139.","journal-title":"J Pak Med Assoc"},{"issue":"10","key":"511_CR36","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1210\/jc.2009-0942","volume":"94","author":"W Bonfig","year":"2009","unstructured":"Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab. 2009;94(10):3882\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"511_CR37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1056\/NEJMoa040367","volume":"351","author":"MBMDM Leonard","year":"2004","unstructured":"Leonard MBMDM, Feldman HIMDM, Shults JP, Zemel BSP, Foster BJMDM, Stallings VAMD, Long-Term. High-Dose glucocorticoids and bone mineral content in childhood Glucocorticoid-Sensitive nephrotic syndrome. N Engl J Med. 2004;351(9):868\u201375.","journal-title":"N Engl J Med"},{"issue":"1","key":"511_CR38","first-page":"1","volume":"33","author":"L Kang","year":"2011","unstructured":"Kang L, Dian-Chi Z, Qi-Yong W, Hui-Juan Z, Feng-Yang G, Hui P, et al. Effect of long term glucocorticoid treatment on human growth hormone secretion in children and adolescents and the safety and effectiveness of Recombinant human growth hormone treatment. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011;33(1):1\u20134.","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"1","key":"511_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1752-1947-2-186","volume":"2","author":"S Lehmann","year":"2008","unstructured":"Lehmann S, Ott H. Glucocorticoid hypersensitivity as a rare but potentially fatal side effect of paediatric asthma treatment: A case report. J Med Case Rep. 2008;2(1):186.","journal-title":"J Med Case Rep"},{"issue":"Supplement 2","key":"511_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2017-eular.3179","volume":"76","author":"I Foeldvari","year":"2017","unstructured":"Foeldvari I, Anton J, Friswell M, Bica B, De Inocencio J, Aquilani A, et al. Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients. Ann Rheum Dis. 2017;76(Supplement 2):399\u2013400.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"511_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaad.2022.12.028","volume":"88","author":"SB Sloan","year":"2023","unstructured":"Sloan SB. This month in JAAD case reports: March 2023: Tocilizumab for refractory morphea. J Am Acad Dermatol. 2023;88(3):547.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 106","key":"511_CR42","first-page":"211","volume":"35","author":"G Martini","year":"2017","unstructured":"Martini G, Campus S, Raffeiner B, Boscarol G, Meneghel A, Zulian F. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Exp Rheumatol. 2017;35(Suppl 106):211\u20133.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"511_CR43","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/pde.15350","volume":"40","author":"AT Ng","year":"2023","unstructured":"Ng AT, Brandling-Bennett HA, Drolet BA, Siegel DH, Chiu YE. Presenting characteristics and progression of pediatric-onset morphea: interim analysis of a prospective registry. Pediatr Dermatol. 2023;40(4):606\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"14","key":"511_CR44","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.7150\/ijbs.75876","volume":"18","author":"Y Li","year":"2022","unstructured":"Li Y, Zhao J, Yin Y, Li K, Zhang C, Zheng Y. The role of IL-6 in fibrotic diseases: molecular and cellular mechanisms. Int J Biol Sci. 2022;18(14):5405\u201314.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"511_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","volume":"10","author":"J Wei","year":"2011","unstructured":"Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev. 2011;10(5):267\u201375.","journal-title":"Autoimmun Rev"},{"key":"511_CR46","doi-asserted-by":"crossref","unstructured":"Liu S, Xiao X, Yue F, Su C, Tong Y, Xu W. Case report: systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman. Front. 2024;15.","DOI":"10.3389\/fimmu.2024.1487508"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00511-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:05:50Z","timestamp":1778756750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-025-00511-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00511-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Anhui Province Children\u2019s Hospital review board (EYLL-2025-049), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}